December 27, 2014 6:35 AM ET

Pharmaceuticals

Company Overview of Neurim Pharmaceuticals (1991) Ltd.

Company Overview

Neurim Pharmaceuticals (1991) Ltd. operates as a drug discovery and development company. It focuses on age-related disorders in the central nervous system. The company provides Circadin, a prolonged release melatonin for insomnia. Its products include orlogin, for circadian rhythm disorders; Neu-120, which has been developed as adjunct therapy to levodopa in patients with motor fluctuations; Neu-P11, a melatonin agonist binds with high affinity to melatonin receptors; and Neu-105 for the treatment of asthma. The company was founded in 1991 and is based in Tel-Aviv, Israel.

8 Hanechoshet St.

Tel-Aviv,  69710

Israel

Founded in 1991

Phone:

972 3 768 4911

Fax:

972 3 649 4568

Key Executives for Neurim Pharmaceuticals (1991) Ltd.

Founder and President
Age: 72
Founder and Chief Scientific Officer
Chief Operating Officer and Chief Financial Officer
Managing Director
Head of Investor Relations
Compensation as of Fiscal Year 2014.

Neurim Pharmaceuticals (1991) Ltd. Key Developments

Neurim Pharmaceuticals (1991) Ltd. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Neurim Pharmaceuticals (1991) Ltd. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Neurim Pharmaceuticals Announces Publication of Positive Effects of Add-on Circadin® in Alzheimer's Disease Patients

Neurim Pharmaceuticals announced publication of the results from an exploratory Phase 2 randomized placebo-controlled clinical trial evaluating the safety and efficacy of add-on Circadin(R) (Prolonged Release melatonin 2mg) to standard therapy in Alzheimer's disease (AD) patients. The study, published in the Clinical Interventions in Aging Journal, demonstrates positive effects of the drug on cognitive performance and sleep maintenance in the AD patients. In this study, 80 patients diagnosed with mild-to-moderate Alzheimer's disease, with and without insomnia co-morbidity, receiving standard therapy (acetylcholinesterase inhibitors with or without memantine) were randomly assigned in a double-blind manner to 2 mg of Circadin(R) or placebo treatment nightly for 24-weeks. The paper reports that patients treated with Circadin(R) for 6 months had significantly better cognitive performance than those with placebo as measured by Instrumental Activities of Daily Living (IADL) and Mini Mental State Examination (MMSE). Mean Alzheimer's Disease Assessment Scale - cognition (ADAS-Cog) did not differ between groups. Sleep efficiency as measured by Pittsburgh Sleep Quality Index (PSQI) Component 4 also improved with Circadin(R). In a subgroup of patients suffering from comorbid insomnia, Circadin(R) treatment resulted in significant and clinically meaningful effects vs. placebo in mean IADL (p=0.032), MMSE (+1.5 vs. -3 points, p=0.0177) sleep efficiency (p=0.04), and median ADAS-Cog values (-3.5 vs. +3 points, p=0.045). The treatment was well tolerated.

Neurim Pharmaceuticals (1991) Ltd. Presents at ChinaBio(R) Partnering Forum 2014, May-08-2014 02:15 PM

Neurim Pharmaceuticals (1991) Ltd. Presents at ChinaBio(R) Partnering Forum 2014, May-08-2014 02:15 PM. Venue: Kempinski Hotel Suzhou, Suzhou, China.

Similar Private Companies By Industry

Company Name Region
Tulip Medical Ltd. Middle East/Africa
Yamit Biotechnologies Ltd. Middle East/Africa
Pep2Life Middle East/Africa
cCAM Biotherapeutics Ltd. Middle East/Africa
CytoD Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Neurim Pharmaceuticals (1991) Ltd., please visit www.neurim.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.